Alligator Bioscience: Q4 2022, Successful Readout with Mitazalimab - Redeye

Redeye comments on Alligator’s Q4 report. The key event during the quarter was mitazalimab showing strong results (an ORR of 52%) in the interim readout from OPTIMIZE-1, which derisks the clinical development.

Länk till analysen i sin helhet: https://www.redeye.se/research/874884/alligator-bioscience-q4-2022-successful-readout-with-mitazalimab?utm_source=finwire&utm_medium=RSS